The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Second-line therapy following osimertinib in metastatic EGFR-mutated non-small cell lung cancer at an academic medical center.
 
Michael Rafizadeh
Stock and Other Ownership Interests - Lilly; Natera
 
Stephanie Bogdan
No Relationships to Disclose
 
Jonathan Lee
No Relationships to Disclose
 
Nasser Altorki
Stock and Other Ownership Interests - Angiocrine Bioscience; tomorrow; View Point Medical
Research Funding - Regeneron
(OPTIONAL) Uncompensated Relationships - Nucleus Global
 
Xi Zhou
No Relationships to Disclose
 
Ashish Saxena
Honoraria - Advarra; Galvanize; Galvanize Therapeutics; MJH Healthcare Holdings, LLC; OncLive/MJH Life Sciences; PER
Consulting or Advisory Role - Boehringer Ingelheim; Bristol Myers Squibb; G1 Therapeutics; Galvanize Therapeutics; InxMed; Novocure
Research Funding - Alphamab (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences; Celgene (Inst); Daiichi Sankyo (Inst); Endocyte (Inst); Genentech (Inst); Guardant Health (Inst); Immunomedics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novocure (Inst); Regeneron (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Top Alliance BioScience (Inst); VM Pharma (Inst)
 
Christine Garcia
Honoraria - Johnson & Johnson/Janssen; Pfizer; Regeneron
Consulting or Advisory Role - Pfizer
 
Bobak Parang
No Relationships to Disclose